{
    "name": "gadopiclenol",
    "comment": "Rx",
    "other_names": [
        "Elucirem",
        "Vueway"
    ],
    "classes": [
        "Gadolinium-Containing Contrast Agents"
    ],
    "source": "https://reference.medscape.com/drug/elucirem-vueway-gadopiclenol-4000325",
    "pregnancy": {
        "common": [
            "GBCAs cross the placenta and result in fetal exposure and gadolinium retention",
            "Human data on the association between GBCAs and adverse fetal outcomes are limited and inconclusive"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Estimated infant exposure is 0.01%-0.04% of the maternal dose",
            "Data are not available regarding presence of gadopiclenol in human milk, effects on breastfed infants, or effects on milk production"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Nephrogenic systemic fibrosis (NSF)",
                    "description": [
                        "Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired drug elimination",
                        "Avoid use in these patients unless diagnostic information is essential and not available with noncontrast MRI or other modalities",
                        "NSF may result in fatal or debilitating fibrosis affecting skin, muscle, and internal organs",
                        "Risk of NSF highest with chronic, severe kidney disease (ie, GFR <30 mL/min/1.73 m",
                        "2",
                        ") or acute kidney injury",
                        "Screen for acute kidney injury and other conditions that may reduce renal function; for patients at risk for chronically reduced renal function (eg, age >60 years, hypertension, diabetes), estimate GFR through laboratory testing",
                        "For patients at highest risk for NSF, do not exceed recommended dose and allow sufficient time for drug elimination before readministration"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "History of hypersensitivity reactions to gadopiclenol"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Gadolinium-based contrast agents increase risk for NSF among patient with impaired drug elimination (see Black Box Warnings)",
                "Anaphylactic and anaphylactoid reactions reported and may involve cardiovascular, respiratory, and/or cutaneous manifestations, including reports of patients experiencing cardiovascular collapse and death",
                "Acute kidney injury requiring dialysis has occurred in patients with chronically reduced renal function; serum creatinine levels and estimated GFR may not reliably assess renal function in setting of acute kidney injury",
                "Injection site extravasation reported",
                "GBCAs may impair visualization of lesions seen on noncontrast MRI; caution when MRI scans interpreted without a companion noncontrast MRI scan"
            ],
            "specific": [
                {
                    "type": "Nephrogenic systemic fibrosis (NSF)",
                    "description": [
                        "Gadolinium-based contrast agents increase risk for NSF among patient with impaired drug elimination (see Black Box Warnings)",
                        "Report any diagnosis of NSF following administration to Guerbet LLC (1-877-729-6679) or FDA (1-800-FDA-1088 or ",
                        "www.fda.gov/medwatch",
                        ")",
                        "For patients receiving hemodialysis, physicians may consider prompt initiation of hemodialysis following administration of a GBCA in order to enhance contrast agentâ€™s elimination; the usefulness of hemodialysis in prevention of NSF is unknown"
                    ]
                },
                {
                    "type": "Gadolinium retention",
                    "description": [
                        "Gadolinium is retained for months or years in several organs",
                        "Highest concentrations (nanomoles per gram of tissue) have been identified in bone, followed by other organs (eg, brain, skin, kidney, liver, and spleen)",
                        "Duration of retention also varies by tissue and is longest in bone",
                        "Patients requiring multiple lifetime doses, pregnant and pediatric patients, and patients with inflammatory conditions are at higher risk of gadolinium retention",
                        "Consequences of gadolinium retention in the brain have not been established",
                        "Pathologic and clinical consequences of GBCA administration and retention in skin and other organs have been established in patients with impaired renal function",
                        "Rare reports of pathologic skin changes in patients with normal renal function"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Maculopapular rash",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        },
        {
            "name": "Worsened renal impairment",
            "percent": null
        },
        {
            "name": "Feeling hot",
            "percent": null
        },
        {
            "name": "Pyrexia",
            "percent": null
        },
        {
            "name": "Oral paresthesia",
            "percent": null
        },
        {
            "name": "Dysgeusia",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "Pruritus",
            "percent": null
        },
        {
            "name": "Allergic dermatitis",
            "percent": null
        },
        {
            "name": "Erythema",
            "percent": null
        },
        {
            "name": "Injection site paresthesia",
            "percent": null
        },
        {
            "name": "Cystatin C increase",
            "percent": null
        },
        {
            "name": "Blood creatinine increased",
            "percent": null
        }
    ]
}